Bile Duct Cancer

Bile duct cancer, also known as cholangiocarcinoma, is a rare and aggressive form of cancer that affects the bile ducts, which are small tubes that carry bile from the liver to the small intestine. At Alfa Cytology, we are committed to helping our clients unravel the complexity of these diseases by providing integrated preclinical research solutions.

Introduction to Bile Duct Cancer

According to the American Cancer Society, bile duct cancer is particularly common in Southeast Asian countries due to parasitic infections, which cause cancer in the bile duct region of the body. Bile duct cancer is a heterogeneous disease, meaning it can vary in terms of its location, stage, and biological characteristics. It can arise from different parts of the bile ducts, including the intrahepatic (inside the liver) and extrahepatic (outside the liver) regions. This complexity poses significant challenges in diagnosis and treatment planning. Therefore, it is essential to develop tailored treatment strategies that take into account the specific characteristics of each person's disease.

Fig.1 Statistical map of incidence and mortality data of bile duct cancer. (Credit the National Cancer Institute as the source.)

Therapy Development for Bile Duct Cancer

Currently, the therapeutic options for cholangiocarcinoma include surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy. At the present stage, targeted therapy for cholangiocarcinoma is used for patients with relevant gene mutations, and the only targeted drugs that have been clearly approved for cholangiocarcinoma indications in the world are the two targets of FGFR and IDH, which are pemetinib, fobacitinib, and everolimus, respectively. Common gene mutations in cholangiocarcinoma include FGFR2, PARP, IDH1/2, KRAS, SMAD4, CDKN2A/B, etc., which determines the future direction of targeted drug development.

Our Services

The surge in market size highlights the growing demand for effective and innovative therapeutic options for bile duct cancer. Alfa Cytology is at the forefront of providing comprehensive and innovative solutions for cholangiocarcinoma. With our state-of-the-art preclinical research facilities and a specialized team of biologists and scientists, we are dedicated to advancing the understanding and treatment of this complex disease. Our services include but are not limited to:

Modeling Services of Bile Duct Cancer

Animal Models

Xenograft Models

• Patient-Derived Xenograft (PDX) Model
• Cell Line Xenograft (CDX) Model

Genetically Engineered Mouse Models (GEMMs)

Cell Line Models

• HuCCT1
• TFK-1
• Mz-ChA-1

Organoids

Derived from:

• Patient Tumor Samples
• Induced Pluripotent Stem Cells (iPSCs)

Optional Species

• Mouse
• Rats
• Zebrafish
• Non-human Primates
• Others

At Alfa Cytology, we are committed to the research and study of bile duct cancer, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. For more information about our anal cancer research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us.

For research use only.